phase 2_completion
saveMerck & Co Inc — pembrolizumab (Phase II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Gliosarcoma
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 1 initiationNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)Apr 27, 2026 · 161d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalApr 6, 2026 · 182d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalFeb 10, 2026 · 237d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalNov 21, 2025 · 318d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJul 24, 2025 · 438d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJun 12, 2025 · 480d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJun 6, 2025 · 486d ago
- approvalKEYTRUDA (PEMBROLIZUMAB) — FDA approvalJun 3, 2025 · 489d ago
same company · ±60 days · 4
- earningsMerck & Co., Inc. earningsApr 30, 2026
- phase 1 initiationMK-6050: Merck & Co Inc — MK-6050 (Phase I Trial Initiation)Apr 30, 2026
- phase 2 completiontulisokibart: Merck & Co Inc — tulisokibart (Phase II Trial Completion)Apr 30, 2026
- pdufa(doravirine + islatravir hydrate): Merck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)Apr 28, 2026
related news · 8
- biopharma diveMerck ADC, licensed from China, hits mark in first big global trial
- biopharma diveRegeneron immunotherapy combo comes up short in melanoma trial
- onclivePembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC
- oncliveRintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
- oncliveBiomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy
- oncliveDr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
- oncliveHonesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
- oncliveDr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma
🐶 often sniffed alongside
top 8- drugKEYTRUDA515 co-mentions · 131 sources
- tagApproval512 co-mentions · 128 sources
- drugKEYTRUDA QLEX269 co-mentions · 131 sources
- drugCancer Program256 co-mentions · 128 sources
- drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
- tagGlioblastoma2 co-mentions · 1 sources
- drugaxelopran1 co-mentions · 1 sources
- companyNational Institute of Neurological Disorders and Stroke1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that